EAM
EWTX icon

Exome Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Exome Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,046
Closed -$2.48M – 62
2025
Q4 		$2.48M Sell
100,046
-73,393
-42% -$1.47M 1.19% 35
2025
Q3 		$2.81M Buy
173,439
+48,969
+39% +$695K 1.7% 22
2025
Q2 		$1.63M Buy
124,470
+53,032
+74% +$765K 1.21% 38
2025
Q1 		$1.57M Sell
71,438
-10,035
-12% -$263K 1.4% 32
2024
Q4 		$2.18M Buy
81,473
+21,573
+36% +$687K 1.63% 24
2024
Q3 		$1.6M Buy
+59,900
New +$1.19M 1.08% 40

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Exome Asset Management's EWTX Position: Q1 2026 in Review

Exome Asset Management sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 100,046 shares — an estimated $2.48M sold.

Exome Asset Management first reported a position in EWTX in Q3 2024 and held it in 6 quarters. The position peaked at $2.81M in Q3 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Exome Asset Management reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 100,046 Edgewise Therapeutics shares in Q1 2026, an estimated $2.48M.
  • Exome Asset Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 6 quarters.
  • Exome Asset Management's Edgewise Therapeutics position peaked at $2.81M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.